Effect of Antihypertensive Drugs on Glaucoma Patients

June 27, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
It has been reported that among Asian non-glaucomatous, antihypertensive medications were associated with retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness. In order to explore whether antihypertensive medications would influence the neuropathy among glaucomatous population, we designed a cross-sectional observational study to analyze the retinal status among glaucoma patients with use of antihypertensive medication.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

we designed a cross-sectional obeservational study to analyze the retinal status among glaucoma patients with use of hyertensive medication.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Kaijun Wang, MD
  • Phone Number: +86 13600529217
  • Email: wkj992@126.com

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Recruiting
        • 2nd Affiliated Hospital, School of Medicine, Zhejiang University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

outpatient from ophthalmology and cardiology clinic

Description

Inclusion Criteria:

  • age no less than 18 years

    • best corrected visual acuity better than decimal 0.3

Exclusion Criteria:

  • secondary glaucoma

    • secondary hypertension
    • glaucoma-related operation history
    • pregnancy or lactation period
    • uncooperative with retinal examination
    • severe opacity with refracting media in eye
    • severe retinal diseases and neuropathy
    • congenital retinal optic nerve abnormality
    • other systemic diseases that influence hypertension and glaucoma assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
healthy control
adults without glaucoma history or hypertension history
Other: no intervention
no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
glaucoma patients
adults with primary glaucoma history; without glaucoma-related operation history; without hypertension history
Other: no intervention
no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
hypertension patients
adults with primary hypertension history; without glaucoma history
Other: no intervention
no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
glaucoma+hypertension
adults with primary glaucoma history and primary hypertension history; without glaucoma-related operation history
Other: no intervention
no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
retinal nerve fiber layer thickness
Time Frame: within 3 months from recruitment
retinal nerve fiber layer thickness measured by optical coherence tomography
within 3 months from recruitment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Investigators

  • Principal Investigator: Kaijun Wang, MD, Second Affiliated Hospital of College of Medicine, Zhejiang University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2021

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

December 31, 2022

Study Registration Dates

First Submitted

June 16, 2021

First Submitted That Met QC Criteria

June 27, 2021

First Posted (Actual)

June 29, 2021

Study Record Updates

Last Update Posted (Actual)

June 29, 2021

Last Update Submitted That Met QC Criteria

June 27, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-0287

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma

Clinical Trials on no intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe